Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients

Elizabeth Bishop Gausden,1 Matthew R Garner,2 Stephen J Warner,1 Ashley Levack,1 Andrew M Nellestein,3 Tiffany Tedore,4 Eva Flores,5 Dean G Lorich3

ABSTRACT

Introduction: There is a high incidence of blood transfusion following hip fractures in elderly patients. Tranexamic acid (TXA) has proven efficacy in decreasing blood loss in general trauma patients as well as patients undergoing elective orthopaedic surgery. A randomised controlled trial will measure the effect of TXA in a population of patients undergoing hip fracture surgery.

Methods: This is a double-blinded, randomised placebo-controlled trial. Patients admitted through the emergency room that are diagnosed with an intertrochanteric or femoral neck fracture will be eligible for enrolment and randomised to either treatment with 1 g of intravenous TXA or intravenous saline at the time of skin incision. Patients undergoing percutaneous intervention for non-displaced or minimally displaced femoral neck fractures will not be eligible for enrolment. Postoperative transfusion rates will be recorded and blood loss will be calculated from serial haematocrits.

Ethics and dissemination: This protocol was approved by the Institutional Review Board (IRB) and is registered with clinicaltrials.gov. The findings of the trial will be disseminated through peer-reviewed journals and conference presentations.

Trial registration number: NCT01940536.

INTRODUCTION

Hip fractures in the elderly remain a pressing public health issue in the USA given the aging population.1 Hip fractures are associated with numerous adverse events and increased mortality up to 1 year after the event.2-5 Hidden blood loss in hip fractures, in addition to intraoperative blood loss, may be as high as 1500 cc.6 7 The rate of blood transfusion in the perioperative period for hip fracture patients is reported between 20% and 60%.8-11 Total blood loss, and thus rate of transfusion, is greater for extracapsular hip fractures compared to intracapsular hip fractures.11 A meta-analysis of 20 studies found a significantly increased risk of postoperative bacterial infection in patients who receive an allogenic blood transfusion in the perioperative period.12 In addition to the increased risk of infection, patients who require blood transfusion following hip fracture have an increased hospital length of stay.13 Furthermore, an allogenic blood transfusion in the USA was recently estimated to increase costs by $1731 per admission.14

Numerous antifibrinolytics have been used to limit bleeding in orthopaedic surgery and prevent the need for blood transfusion.15-19 One of these antifibrinolytics, tranexamic acid (TXA), is a synthetic derivative of the amino acid lysine and acts as a competitive inhibitor in the activation of plasminogen to plasmin, therefore preventing the degradation of fibrin. As a result of the CRASH-2

Strengths and limitations of this study

- A prospective, randomised, placebo-controlled trial is the optimal study design to address the question of efficacy of tranexamic acid (TXA) use in patients with hip fractures.
- The outcomes will be reported based on 1-year follow-up, which is longer follow-up than any other study examining TXA use in patients with hip fractures.
- Findings will provide objective data from which clinicians can base future guidelines regarding TXA administration.
- Recruitment is slow as patients and healthcare proxies are wary of enrolling in a study in a trauma setting.
Numerous studies have investigated the safety and efficacy of TXA in patients undergoing elective orthopaedic surgery, including total joint replacement and spine surgery. The consensus from this literature is overwhelmingly in favour of administration of TXA given the decrease in blood loss, transfusion rates and cost. Although several individual studies have found increased risk of thromboembolic events in groups receiving TXA, larger studies and meta-analyses have uniformly found no increased risk of thrombosis.

Patients who suffer hip fractures frequently have multiple comorbidities making them more susceptible to adverse events from blood loss. The most common comorbidities of individuals with hip fractures are congestive heart failure, chronic pulmonary disease and diabetes. Administering TXA to such patients has a potential to offset blood loss, improve patient outcomes and lower cost of care by decreasing the rate of transfusions.

In designing this study, we concluded that hip fracture surgery, which demonstrated reduced mortality in trauma patients who received TXA, the WHO added TXA to the essential drugs list. Currently TXA is not routinely used in patients with hip fractures in the USA, despite its common use worldwide and proven efficacy in reducing blood loss in other populations.

In a retrospective cohort study, Lee et al similarly reported a transfusion rate three times lower in patients who received TXA prior to hemiarthroplasty. In a separate randomised controlled trial that compared intravenous administration of TXA to topical TXA administration as well as placebo in hip fracture patients undergoing hemiarthroplasty, both of the TXA groups experienced less blood loss.

In designing this study, we concluded that hip fracture patients are both likely to experience significant blood loss and are susceptible to the adverse effects of blood loss making them an ideal population to target for a randomised controlled trial of the effects of perioperative TXA on blood loss. We hypothesise that administration of TXA will decrease blood loss in hip fracture patients and lower the rate of allogeneic blood transfusion.

Objective
To investigate the hypothesis that TXA will lower blood loss and transfusion rate in patients with hip fractures.

Methods and analysis
Overview of trial design
We are conducting a single-centre randomised controlled trial using a parallel two-arm design to investigate whether perioperative TXA use will decrease the rate of transfusion in patients with hip fractures (figure 1). Randomisation will be stratified by type of hip fracture (ie. intertrochanteric vs femoral neck fracture). The surgical team, anesthesia team and patients will be blinded to the assignment. Once consent is obtained and a patient is enrolled, a 1:1 randomisation system will be employed by our institution’s investigational pharmacy to assign patients to receive TXA or placebo. Patient enrolment will occur over ~2 years and enrolled patients will be followed for 1 year postoperatively. Incidence of blood transfusion, total calculated blood loss, and acute adverse events (transfusion reaction, cerebrovascular accident (CVA), myocardial infarction, pulmonary embolism, symptomatic deep vein thrombosis (DVT), surgical site infection (SSI), and death) will be assessed in the perioperative period. Patients will also be assessed at 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively to capture long-term adverse events as well as determine mortality rate. This trial is registered (NCT01940536) and has received ethical approval from the Weill Cornell Medical College Institutional Review Board (IRB# 1301013463).

Primary research question
In patients with hip fractures, does a single bolus of TXA at the time of surgery result in a lower rate of blood transfusion?

Secondary research question
In patients with hip fractures, does a single bolus of TXA at the time of surgery result in:
1. Decreased calculated blood loss?
2. Shorter length of hospitalisation?
3. Differences in occurrence of adverse events?

Hypothesis
As a primary outcome, there will be a decreased rate of blood transfusion in patients who receive TXA intraoperatively and no significant increase in frequency or severity of adverse events in comparison to patients who receive placebo. This study is powered to address the primary outcome of difference in transfusion rates between the two study arms for intracapsular and extracapsular hip fractures.

Setting and participants
Adult patients (over 18 years of age) presenting to a single tertiary care centre with an acute hip fracture will be screened for eligibility. All patients with hip fractures at this institution are admitted to the Medical Orthopaedic Trauma Service (MOTS). Prior to surgery, patients older than 75 years of age, or those with medical comorbidities will be optimised by the general medical service prior to surgery. All potentially eligible patients will be screened and documented as (1) eligible and included, (2) eligible and missed or (3) excluded.
The study coordinator will obtain informed consent for participation in the study using the approved IRB Informed Consent forms. All patients will provide written informed consent and will understand that by entering into the study they may receive either placebo or TXA. Participation in the study is voluntary and their decision to participate will not affect any other aspect of their care in case of refusal. Patients will have the right to withdraw from the study at any point.

Inclusion criteria
Patients admitted through the emergency department or transferred to our institution who meet the following criteria will be included in the study:
- Adults over the age of 18
- Acute intertrochanteric or femoral neck hip fracture
- Patients treated surgically with cephalomedullary nail, hemiarthroplasty or total hip arthroplasty (THA)

Exclusion criteria
Patient who meet any one or more of the following criteria will be excluded from the study:
- Use of any anticoagulant at the time of admission (e.g., vitamin K antagonists, antithrombin agents, antiplatelet agents or factor IIa and Xa inhibitors)
- Documented allergy to TXA
- History of DVT or pulmonary embolus
- Hepatic dysfunction (aspartate transaminase (AST) / alanine transaminase (ALT)>60)
- Renal dysfunction (Cr >1.5 of glomerular filtration rate (GFR)>30)
- Active coronary artery disease (event in the past 12 months)
- History of CVA in the past 12 months
- Presence of a drug-eluting stent
- Colour blindness
- Leukaemia or any active cancer
- Coagulopathy based on admission laboratory values (international normalised ratio (INR)>1.4, partial

Figure 1 Study Design (TXA: tranexamic acid; PRBC: packed red blood cells).
thromboplastin time (PTT) >1.4× normal, platelets <50 000)

- Non-displaced femoral neck fractures treated percutaneously

Baseline assessment includes sex; birth date; height and weight; mechanism of injury; time from injury to presentation to our institution; American Society of Anesthesiologists (ASA) classification; Charlson Comorbidity Index; and comorbidities including diabetes, cardiovascular disease, pulmonary disease, peripheral vascular disease, dementia, hypertension and history of smoking. The haemoglobin and haematocrit will be recorded at the time of admission and on the morning of surgery.

Blinding
After consent and enrolment in the study, patients will be stratified based on the type of hip fracture (intracapsular or extracapsular). Following stratification by fracture type, the institution’s investigational pharmacist will perform the randomisation and assign the patient to either receive TXA or placebo. Patients will be randomised in blocks of 20. The packaging of the injections will be performed by the investigational pharmacy and will be identical for TXA and placebo. All patients and clinicians, with the exception of the pharmacist, will remain blinded until the data is analysed.

Intervention
The patients randomised to the treatment arm will receive 1 g of intravenous TXA mixed in 100 cc of saline, bolused at the time of surgical incision. Those assigned to the placebo group will receive an equivalent volume bolus of saline at the time of surgical incision.

Patients with intertrochanteric hip fractures will be treated with a long intramedullary hip screw implant with a trochanteric start point. Patients with displaced femoral neck fractures will be treated with a cemented or non-cemented hemiarthroplasty or THA at the discretion of the treating surgeon. All surgeries will be supervised by the attending surgeon with the assistance of orthopaedic residents. The surgical technique as well as the anaesthetic technique (regional vs general anaesthesia) will be recorded and assessed in the final analysis. The time from injury to surgery will also be recorded and included in the analysis.

Blood transfusion criteria will remain consistent with hospital standards (Hb<8 g/dL or symptomatic anaemia) as determined by an independent, blinded medical team who will follow the patient throughout the hospital stay. Number of blood transfusions received will be documented on patient discharge. Haematocrit and haemoglobin will be recorded daily for all patients while they remain in the hospital. Further monitoring will be conducted based on need as determined by the independent medical team. Estimated blood volume will be calculated using baseline height, weight and gender and the laboratory values will be used to calculate estimated blood loss postoperatively (see online supplementary appendix 1).

All patients will be permitted to weight-bear as tolerated postoperatively and DVT prophylaxis will be standardised. All enrolled patients will receive subcutaneous heparin, 5000 units every 8 hours beginning on admission until 12 hours prior to surgery and restarting 6 hours after surgery. Calf mechanical compression devices will also be utilised during the inpatient stay and will remain on at all times with the exception of physical therapy sessions. Following discharge from the hospital patients will be given aspirin 325 mg twice daily for DVT prophylaxis for a total of 6 weeks. Diagnostic studies to assess for thromboembolic events (ie, DVT, pulmonary embolism, and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use.

Primary outcome
The primary outcome of the study will be the rate of blood transfusion from the time of surgery until discharge. Patients will be monitored with serial haemoglobin and haematocrit measurements and their vital signs will be recorded as per the standard of care to determine the need for blood transfusion. Only intraoperative and postoperative blood transfusions will be considered for the primary outcome measure as the drug will be administered at the time of surgical incision. Therefore, we anticipate that TXA administration in this study will only modify the rate of intraoperative or postoperative transfusion, and have no effect on the rate of preoperative transfusion in this population.

Secondary outcome
The secondary study outcomes include the calculated blood loss (calculated based on validated methods as outlined in online supplementary appendix 1), frequency of adverse events (including transfusion reaction, myocardial infarction, symptomatic DVT, pulmonary embolus, CVA, reoperation, readmission, infection and death) (figure 1).

For the study purposes, a transfusion reaction will be defined as any constellation of symptoms during a blood transfusion that necessitate discontinuation of the transfusion.

Myocardial infarction will be defined as a cardiologist diagnosis of myocardial infarction based on a combination of ECG changes, echocardiogram changes, or creatine kinase MB or troponin changes. A pulmonary embolism must be confirmed by pulmonary angiography, CT scan of the chest, echocardiographic visualisation or visualisation of thrombus at autopsy. A symptomatic DVT must be confirmed by venography, CT scan, MRI, or pathological evidence at autopsy. A CVA must be diagnosed by a neurologist and will be defined as an embolic, thrombotic or hemorrhagic vascular accident or stroke with motor, sensory or cognitive dysfunction that persists for longer than 24 hours.
A SSI will be defined as either superficial or deep infection. Superficial SSI involves only skin or subcutaneous tissue while a deep SSI extends deep to the fascial and muscle layers. Reoperation is defined as any return to the operating room for a procedure related to the fractured hip.

**Sample size consideration**

Our institutional transfusion rate was calculated based on a random sample of 60 patients and was 65% for extracapsular hip fractures and 35% for intracapsular hip fractures, for an overall transfusion rate of 49%. The average reduction in transfusion rate in the previous five studies using TXA was 20%. We plan to include a total of 338 patients (146 intracapsular hip fractures and 192 extracapsular hip fractures). This study design will achieve 81% power to detect a reduction in blood transfusion from 65% in the placebo control group to 45% in the TXA group with statistical significance set to α equal to 0.05 for the extracapsular hip fracture group. Similarly the study will achieve 81% power to detect a reduction in blood transfusion from 35% in the placebo control group to 15% in the TXA group with statistical significance set to α equal to 0.05 for the intracapsular hip fracture group.

**Data analysis plan**

Descriptive analyses of the patient population will include reporting means (with SDs) for continuous variables and frequencies (with percentages) for categorical or discrete variables. A χ² analysis will be conducted to evaluate the superiority of TXA in reducing the rate of transfusion in the TXA group versus the placebo control group. The analysis and reporting of the results of the clinical outcomes will follow the CONSORT guidelines (http://www.consort-statement.org). We will conduct a multiple logistic regression model to determine if type of fracture (intracapsular or femoral neck), comorbidities, Charlson comorbidity index, age, time to surgery and mechanism of injury are related to transfusion administration. Similarly we will conduct a multiple linear regression model to determine which variables are related to blood loss. We will also conduct subgroup analyses to determine if the effect of TXA is modified by fracture type (intracapsular or femoral neck).

Our a priori hypothesis, based on retrospective data, is that patients with intracapsular fractures incur more blood loss than femoral neck fractures and will have a higher rate of transfusion. If these subgroup analyses are underpowered, the subgroup data will be used to generate further hypotheses to be tested in the future. All analyses will be performed using Stata 14.0 software (Stata Corporation, College Station, Texas, USA).

**Data safety monitoring**

The data safety monitoring board has been established to monitor the trial safety and renew the study biannually. This board is independent of the trial and free of conflicts with any of the investigation team.

**DISCUSSION**

There is clinical uncertainty and a lack of high-quality evidence regarding the use of TXA in hip fracture patients. Despite its proven efficacy in elective orthopaedic surgery, the optimal dosing and timing of TXA administration is still debated. Furthermore, the efficacy and side effect profile of TXA in patients with fractures remains unclear. The immediate goal of this trial is to provide high-quality evidence that can be used to develop clinical guidelines for use of TXA in patients with hip fractures.

Patients undergoing elective total joint arthroplasty and elective spine surgery represent a different population from patients who sustain hip fractures. A larger percentage of hip fracture patients have significant medical comorbidities, and many have history of cardiac disease. While TXA has demonstrated safety and efficacy in patients without significant cardiac disease undergoing elective surgery, there is still debate if TXA will have the same effect in patients with significant comorbidities. The data investigating TXA in patients with comorbidities is limited, which has further deterred clinicians from using TXA in patients with hip fractures. However, the potential benefit of decreasing blood loss and decreasing the number of transfusions following hip fracture surgery is overwhelming and will likely result in improved patient outcomes, shorter length of stay and lower cost. The study investigators believe that the potential benefit of TXA in such patients outweighs the risk of TXA. The majority of literature regarding TXA has confirmed its safety and squelched concerns that its use will result in higher rates of thrombosis.

Of the five studies investigating the use of TXA in hip fracture patients, four were randomised controlled trials that were underpowered for detecting significant differences in thromboembolic events (table 1). Furthermore, patients were only followed perioperatively, and differences in 6-month and 1-year mortality rates and late-onset complications were not assessed.

Four of five studies identified a significant decrease in rate of transfusion in patients who received TXA compared to those that did not. The largest study, with a total of 219 patients, was a cohort study with no randomisation. While they found a significant decrease in blood transfusion rate, the study design limits the interpretation of the results secondary to the potential biases of surgeon and patient preference. Several studies excluded all patients with preoperative anemia, which limits the generalisability of their findings. None of the randomised trials provided a detailed analysis of total number of patients excluded from the study at each stage. While the early results from these studies are promising, the overall validity cannot be confirmed without this information. Similarly, there has yet to be a large study to perform a
Table 1: Previously reported outcomes of tranexamic acid (TXA) in hip fracture patients

<table>
<thead>
<tr>
<th>Country</th>
<th>Design</th>
<th>Hip fx (IT or FNF)</th>
<th>TXA regimen</th>
<th>DVT PPX</th>
<th>Sample size</th>
<th>Blood loss (cc)</th>
<th>Transfuse rate %</th>
<th>Thromboembolic events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al 2015</td>
<td>UK</td>
<td>Cohort</td>
<td>Hip arthroplasty only</td>
<td>1 g bolus preoperative Tinzaparin</td>
<td>84/187</td>
<td>–</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Emara et al 2014</td>
<td>Egypt</td>
<td>RCT</td>
<td>Hip arthroplasty only</td>
<td>10 mg/kg bolus, then 5 mg/kg/hour infusion Clexane</td>
<td>20/IV/20</td>
<td>640*</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Zufferey et al 2010</td>
<td>France</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>15 mg/kg bolus preoperative and 3 h later Fondaparinux×35 days (mandatory ultrasound)</td>
<td>57/53</td>
<td>1100*</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>Sadeghi and Mehr-Aein 2008</td>
<td>Iran</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>15 mg/kg bolus preoperative NA</td>
<td>19/4</td>
<td>1178</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td>Vijay et al 2013</td>
<td>India</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>10 mg/kg bolus at surgery NA</td>
<td>45/45</td>
<td>39*</td>
<td>16</td>
<td>0</td>
</tr>
</tbody>
</table>

*Drain output. Thromboembolic events include only symptomatic thromboembolic events.

DVT, deep vein thrombosis; FNF, femoral neck fracture; IT, intertrochanteric; NA, not applicable; PPX, prophylaxis; RCT, randomised controlled trial.

Previously reported outcomes of tranexamic acid (TXA) in hip fracture patients,

Use of TXA in patients with hip fractures

- Thromboembolicevents
- Transfuserate %
- Sample size
- Blood loss (cc)
- Thromboembolic events

Table 1: Use of TXA in patients with hip fractures

<table>
<thead>
<tr>
<th>Country</th>
<th>Design</th>
<th>Hip fx (IT or FNF)</th>
<th>TXA regimen</th>
<th>DVT PPX</th>
<th>Sample size</th>
<th>Blood loss (cc)</th>
<th>Transfuse rate %</th>
<th>Thromboembolic events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al 2015</td>
<td>UK</td>
<td>Cohort</td>
<td>Hip arthroplasty only</td>
<td>1 g bolus preoperative Tinzaparin</td>
<td>84/187</td>
<td>–</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Emara et al 2014</td>
<td>Egypt</td>
<td>RCT</td>
<td>Hip arthroplasty only</td>
<td>10 mg/kg bolus, then 5 mg/kg/hour infusion Clexane</td>
<td>20/IV/20</td>
<td>640*</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Zufferey et al 2010</td>
<td>France</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>15 mg/kg bolus preoperative and 3 h later Fondaparinux×35 days (mandatory ultrasound)</td>
<td>57/53</td>
<td>1100*</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>Sadeghi and Mehr-Aein 2008</td>
<td>Iran</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>15 mg/kg bolus preoperative NA</td>
<td>19/4</td>
<td>1178</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td>Vijay et al 2013</td>
<td>India</td>
<td>RCT</td>
<td>Hip fractures</td>
<td>10 mg/kg bolus at surgery NA</td>
<td>45/45</td>
<td>39*</td>
<td>16</td>
<td>0</td>
</tr>
</tbody>
</table>

*Drain output. Thromboembolic events include only symptomatic thromboembolic events.

DVT, deep vein thrombosis; FNF, femoral neck fracture; IT, intertrochanteric; NA, not applicable; PPX, prophylaxis; RCT, randomised controlled trial.
contributions to the design of the work, planning of data analysis, drafting and revising of the protocol, final approval of the version to be published and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy of the work. EF is the head of the Medical Orthopaedic Trauma Service (MOTS) who organises the medical attendants who manage the patients following surgery. This author made substantial contributions to the design of the work, planning of data analysis, drafting and revising of the protocol, final approval of the version to be published and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy of the work. DGL is the chief of the orthopaedic trauma service at NYP. This author made substantial contributions to the design of the work, planning of data analysis, drafting and revising of the protocol, final approval of the version to be published and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy of the work.

**Funding** This work is supported by a Dr. Thomas Sculco grant and a Dr. Joseph M. Lane grant.

**Competing interests** None declared.

**Ethics approval** Institutional Review Board.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The study has not begun enrolment yet, so there is no data to share at this time. Updates will be available on the clinicaltrials.gov website.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**